FASEB Conference: Genome Engineering: Research and...
CMN Briefs
May. 7, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
eGenesis
Company Type: Therapeutics
Main focus: Development of surrogate human-compatible organs, tissues and cells suitable for transplantation
Company stage: Pre-clinical
Diseases: Liver, kidney and heart transplants
Genome-editing tool: CRISPR
Funding stage: Series C
Location: Cambridge, MA
Website: https://egenesisbio.com/
Pipelinehttps://egenesisbio.com/our-pipeline/
Partners:
eGenesis is pioneering a genome engineering-based approach to develop safe and effective transplantable organs. The eGenesis Genome Engineering and Production (EGEN™) Platform is developed to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering. eGenesis has demonstrated pre-clinical success and is advancing development programmes for acute liver failure, kidney transplant, and paediatric as well as adult heart transplant.
